Transmembrane Protein 184A is a Receptor Required for Vascular Smooth Muscle Cell Responses to Heparin *

Raymond J. Pugh†, Joshua B. Slee†‡, Sara Lynn N. Farwell‡, Yaqiu Li‡, Trista Barthol‡, Walter A. Patton§, Linda J. Lowe-Krentz**

1From the Department of Biological Sciences, 111 Research Drive, Lehigh University, Bethlehem, PA 18015
2Department of Chemistry, 6 West Packer Ave, Lehigh University
3Department of Chemistry, Lebanon Valley College, 101 N. College Avenue, Annville, PA 17003
4Department of Natural Sciences, DeSales University, 2755 Station Avenue, Center Valley, PA 18034

Running title: TMEM184A is a vascular cell heparin receptor
†RJP and JBS contributed equally to this work
**To whom correspondence should be addressed. Phone: (610)758-5084; Fax: (610)758-4004; e-mail: ljlk0@lehigh.edu

Key words: extracellular regulated kinase (ERK), Heparin-binding protein, vascular smooth muscle cells, receptor, signal transduction

ABSTRACT
Vascular cell responses to exogenous heparin have been documented to include decreased vascular smooth muscle cell (VSMC) proliferation following decreased ERK pathway signaling. However, the molecular mechanism(s) by which heparin interacts with cells to induce those responses has remained unclear. Previously characterized monoclonal antibodies that block heparin binding to vascular cells were found to mimic heparin effects. In the present study, those antibodies were employed to isolate a heparin binding protein. Matrix-assisted laser desorption/ionization mass spectrometry (MALDI) data provide evidence that the protein isolated is transmembrane protein 184A (TMEM184A). Commercial antibodies against three separate regions of the TMEM184A human protein were used to identify the TMEM184A protein in VSMCs and endothelial cells. A GFP-TMEM184A construct was employed to determine colocalization with heparin after endocytosis. Knockdown of TMEM184A eliminated the physiological responses to heparin including effects on ERK pathway activity and BrdU incorporation. Isolated GFP-TMEM184A binds heparin and overexpression results in additional heparin uptake. Together, these data support the identification of TMEM184A as a heparin receptor in vascular cells.

For more than 30 years heparin has been known to specifically bind to cells in the vasculature and alter their physiology in addition to its well-recognized function as an anticoagulant. Heparin binds to many proteins including numerous growth factors, cytokines, coagulation factors, cell adhesion molecules, growth factor receptors, matrix glycoproteins, and others (for a review, see 1). In fact, heparin, and the closely related glycosaminoglycan heparan sulfate (HS), interact with more than 400 proteins (2). Heparin decreases endothelial cell (EC) inflammatory gene expression and slows VSMC proliferation (reviewed in 3). Specifically, ECs bind and
endocytose heparin (4,5) which is followed by decreased inflammatory signaling through NF-κB (6) and stress kinase activity (7,8). Heparin binding in VSMCs (9) results in decreases in growth factor-induced ERK signaling (10,11), inhibition of downstream transcription factor activity (12-14), changes in cell cycle inhibitory factors (15), and decreased proliferation (10,16).

Reports of fluorescent heparin uptake into cells where it modulated transcription factor function (17) and requirements of HSPGs for basic growth factor delivery to the nucleus (18), indicate that receptor-mediated uptake of heparin or HS may also be critical for some heparin effects. Similarly, shed HSPG syndecan-1 can be taken up by cells and transported to the nucleus where it alters histone acetylation (19). HS chains are required for uptake, and this uptake can be inhibited by exogenously added heparin. It is likely that the uptake of highly charged heparin and HS chains involves a receptor to manage transport across the membrane. While many heparin-interacting proteins have been linked to specific functions, a receptor responsible for heparin uptake has not been identified.

In addition to heparin uptake into vascular cells, there is clear evidence for heparin/HS binding to growth factors, growth factor receptors, and matrix proteins. A systems analysis of heparin binding proteins suggests that many of the heparin interacting proteins fall into clusters of proteins that are involved with interactions between cells and the extracellular space. Within that broad area, researchers identified clusters involved in control of the immune system, cell-cell communication and control of proliferation (2).

While heparin and HS are structurally similar and based on the same core repeating disaccharide and modifications, heparin is a glycosaminoglycan as compared to HS which typically remains bound to proteoglycan cores associated with cells or matrix (1). In addition, heparin chains have higher levels of sulfation than HS, although both HS and heparin have regions of differing sulfation levels (1). The interactions of heparin or HS with specific extracellular proteins are important in many functions. Therefore, it has often been difficult to assign effects of heparin/HS interactions to any one of these proteins without specific modifications to the heparin interacting protein in question. In vivo, functions characterized as heparin-induced are actually likely to be carried out by one or more HS proteoglycans (HSPGs). Because the many different HSPGs are ubiquitous and the presence of HS is evolutionarily conserved, it has been suggested that heparin binding proteins have actually evolved to interact with HSPGs, and have thus been termed HS binding proteins (1).

In the vasculature, interactions of HSPGs with growth factors and their receptors are crucial in angiogenesis as well as in vascular disease (20). HS/heparin interacts with both growth factors and their receptors and scaffolds proteins; facilitating growth factor dimerization and interaction between growth factors and their receptors (1). The hypothesis that heparin could block HSPG interactions with growth factors and thereby decrease responses to growth factors provides one logical explanation for some of the heparin responses in vascular cells. This hypothesis is supported by studies that indicate transactivation of heparin-binding EGF receptors in response to G protein coupled receptor activation (21). Heparin has even been shown to inhibit Angiotensin II induced VSMC responses (22). Continuing reports of HSPG requirements for cell proliferation in response to activation of additional G protein coupled receptor systems further support the hypothesis that heparin effects are simply due to displacement of HSPG co-receptors (23).

However, heparin interference with HSPG-growth factor interactions cannot explain all of the heparin effects on VSMCs. Specifically, it does not account for the fact that heparin treatment results in turning down cell responses rapidly rather than blocking them from starting (e.g. 10,11). Nor does it address the fact that heparin decreases signaling even when initiated by phorbol esters (12). Heparin induction of p27kip synthesis (15) and DUSP1 (MKP1) expression (24) also occur directly in response to heparin treatment, and high-affinity heparin binding sites and heparin uptake likely involve interactions with a receptor other than growth factors.
To identify and characterize a heparin binding protein(s) that could facilitate heparin uptake and other responses, we created mAbs that specifically block heparin binding to ECs (5). These mAbs (HRmAbs) mimic many heparin effects including blocking VSMC ERK activation and proliferation and inducing DUSP1 synthesis (10,24). These antibodies are able to immunoprecipitate a membrane protein from both ECs and VSMCs that is approximately 45 to 50 kD (5,10).

Recently, we have determined that both HRmAbs and heparin induce signaling through a cGMP-dependent protein kinase (PKG)-dependent pathway to alter VSMC responses to growth factors (14). The antibodies and heparin also alter EC physiology by decreasing JNK and p38 activity and downstream signaling due to JNK and p38 activity (see the accompanying report, 8). These studies all suggest that the antibodies recognize and stimulate a receptor for heparin that exists on both VSMC and ECs. To determine the identity of the protein to which the HRmAbs bind, we hypothesized that HRmAb immunoprecipitates of membrane proteins from vascular cells would contain the protein responsible for heparin effects. We employed both heparin affinity and HRmAb affinity chromatography of membrane proteins and then identified immunoprecipitated protein. Here we report evidence that this procedure isolates the transmembrane protein identified as TMEM184A. Prior studies on TMEM184A are limited, but evidence indicates involvement of the protein in vesicle transport in exocrine cells and Sertoli cells of mice (25,26). Our data presented herein and in the accompanying report (8) indicate that heparin effects on vascular cell physiology are blocked when TMEM184A on the surface is significantly decreased supporting the hypothesis that heparin responses are mediated, at least partially, through TMEM184A which acts as a receptor for heparin.

EXPERIMENTAL PROCEDURES

Materials. Cell culture chemicals, DMEM and MEM, 2.5% trypsin/EDTA, porcine gelatin, heparin, penicillin/streptomycin, PDGF, and glutamine were obtained from Sigma Chemical Co. (St. Louis, MO). Pre-tested FBS was obtained from Invitrogen (Gaithersburg, MD), Atlanta Biologicals (Atlanta, GA) or Biowest (St. Louis MO) and heat-inactivated for 1h at 55° or purchased as heat-inactivated. Anti-active ERK (#4370), anti-BrdU (#5292), and anti-phospho ELK-1 (pELK, #9181) antibodies were from Cell Signaling (Beverly, MA). Anti-DUSP1 (MKP-1, sc-1199), anti-caveolin-1 (sc53564), and anti-TMEM184A (sc292006 N-term domain- NTD, rabbit and sc163460 internal domain- INT, goat) were from Santa Cruz Biotechnology (La Jolla, CA). Anti-TMEM184A (C-terminal domain- CTD, rabbit) was obtained from ProSci Inc. (Poway, CA). Biotinylated anti-GFP (MA5-15256-BTIN) was obtained from ThermoFisher Scientific (Waltham, MA). Secondary antibodies with fluorescent tags or Biotin-labeled (donkey or bovine (for goat primary antibodies), minimal cross-reactivity) were obtained from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). Extra-avidin-alkaline phosphatase™, 5-Bromo-4-chloro-3-indolyl phosphate (BCIP), and nitro blue tetrazolium (NBT) were obtained from Sigma.

Cell Culture. A7r5 rat smooth muscle cells were obtained from ATCC (Rockville, MD). Bovine aortic endothelial cells (BAOECs), bovine aortic smooth muscle cells (BAOSMCs) and rat aortic smooth muscle cells (RAOSMCs) were obtained from Cell Applications, Inc. (San Diego, CA). Commercially available cells were grown as recommended by the supplier and exchanged into MEM media over time before experiments. Human brain microvascular endothelial cells (HBMECs) were obtained from Cell Systems (Kirkland, WA) and cultured using Cell Systems Complete Media before exchange into MEM supplemented identically to BAOEC culture. All vascular cells were cultured on 0.2% porcine gelatin (Sigma)-coated plates or cover slips. Hybridomas were cultured as described previously, and the monoclonal antibodies purified using affinity chromatography (5,10).

Isolation of Heparin Receptor. In a typical experiment, several (12-16) 150-mm dishes of BAOECs were washed with PBS and harvested by scraping with a rubber policeman in a 10% PBS solution, supplemented with two protease inhibitor cocktails (Sigma, P8340 and P2714) used at the
TMEM184A is a vascular cell heparin receptor

manufacturer’s recommended concentrations, homogenized in a dounce homogenizer, and the supernatant collected after centrifugation at 2,000 x g for 10 min to remove nuclei and debris. The supernatant was further centrifuged at 28,000 x g for 1 h at 4°C. All remaining purification steps also contained the protease inhibitor cocktails. The resulting membrane pellet was resuspended in PBS + 0.2% CHAPS. Three to four pellets were combined and the 0.2 % CHAPS/PBS solubilized pellet was subjected to heparin affinity chromatography on heparin agarose. The heparin column was washed with at least five column volumes of 0.2% CHAPS/PBS until the A_{280} reached a baseline absorbance. Heparin-binding proteins were eluted with 1 M NaCl in 0.2% CHAPS/PBS. The eluate was concentrated using an Amicon Ultra-15 Centrifugal Filter Unit (Millipore, Billerica, MA) with a molecular weight cutoff of 10,000, exchanged into 0.2% CHAPS/PBS, and the protein concentration determined using a Lowry assay.

To generate the affinity resin for precipitation, HRmAbs (5,10) were incubated at 25°C for 30 min with a 50-fold molar excess of EZ-link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL). Excess biotin was removed by washing several times with PBS. The biotinylated antibodies were allowed to bind 1.0 ml of streptavidin-modified magnetic beads (Pierce, Rockford, IL) with gentle shaking at 25°C for 1 h. To remove any unbound material, the antibody-magnetic beads solution was washed several times with 0.2 % CHAPS/PBS. One ml of the eluted material from the heparin affinity column was added to the antibody-modified magnetic beads and incubated with gentle shaking at 25°C for 1 h. The beads were localized to the side of the incubation tube using a magnet and the supernatant removed. After several washings with 0.2% CHAPS/PBS (removal of all unbound protein was verified by measuring baseline absorbance at A_{280} in the washings), the magnetic beads were eluted with a 1 M NaCl, 0.2% CHAPS/PBS solution. The eluted material was concentrated using a Centricon-20 plus or an Amicon Ultra-15 Centrifugal Filter Unit (Millipore, Billerica, MA), with a molecular weight cutoff of 10,000, and exchanged into 0.2% CHAPS/PBS. To exchange receptor protein out of CHAPS, TCA was added to 10% (v/v), and the precipitated protein was pelleted by centrifugation. TCA precipitates were processed as noted below.

**PAGE.** Approximately 10 μg TCA-precipitated protein was solubilized in 2X sample buffer and brought to a pH of 8.5 by addition of 1M Tris buffer, pH 8.8. SDS-PAGE was carried out using the Laemmlie system. Direct staining of PAGE gels was accomplished with Coomassie brilliant blue R250 or with SYPRO® Ruby (Sigma). For immunoblotting, gels were transferred and total protein stained with colloidal gold (BioRad, Hercules, CA). For preparative gels, entire TCA precipitated samples were solubilized and separated as above, and gels were stained with SYPRO® Ruby which does not interfere with additional digestion or analysis.

**MALDI Mass Analysis.** For the analysis of the intact protein from an acrylamide gel slice, the gel slice was destained at room temperature (22-23°C) in aqueous 50% methanol/5% acetic acid overnight. The gel slice was then dehydrated with acetonitrile until the slice curled. The slice was then crushed in 100 μl of 100 mM NH₄HCO₃ and incubated at RT for 1 h. The supernatant was removed to a new tube, the extraction of the crushed slice repeated, and the combined extracts lyophilized to dryness. Matrix A (a saturated solution of sinapinic acid [Sigma] in 50% acetonitrile, 0.1% trifluoro acetic acid) was added to the dried sample, the resulting solution spotted (2 x 0.75 μl) on a ground stainless steel target, and analyzed using a Bruker Microflex MALDI-TOF Mass Spectrometer (positive/linear ion mode; at least 100 laser shots; minimum laser power of 60%; 500 ns delayed ion-extraction).

MALDI was also performed on a solution sample of the detergent-solubilized, antibody-purified heparin receptor. A heparan receptor sample (500 μl) was subjected to precipitation with cold acetone (-20°C; overnight). The pellet was redissolved in 10 μl of Matrix A. The supernatant from the acetone precipitation was lyophilized to dryness and resuspended in 10 μl of Matrix A. Each matrix-resuspended sample (1 μl) was spotted on a ground stainless steel target, subjected to on-plate washing with cold water and acetone. In separate experiments, a solution
sample of antibody-purified heparin receptor was precipitated with TCA, resuspended in 100 μl of PBS, and neutralized by adding Tris buffer, pH 8.8. These samples were then extracted four times with a 10-fold excess of water-saturated ethyl acetate to remove any excess CHAPS detergent. The extracted samples were lyophilized, the pellets were resuspended in 20 μl of Matrix A, and were analyzed as above. For publication, spectra were visualized using MoyerZ (Proteometrics) and the peak masses determined from the smoothed spectra (smoothing factor = 10). Data were exported in an ASCII format and plotted in Excel.

For digestion of isolated receptor to peptides, TCA precipitated samples were suspended in 100 μl of water and brought to pH 8.5 by addition of Tris buffer, pH 8.8. Samples were reduced with 10 mM DTT for 30 min at room temperature and acetylated with iodoacetamide to prevent disulfide bonds from reforming. Chymotrypsin (Pierce™, MS grade) digestion was carried out in suspension at 37°C overnight in 100 mM Tris-HCl (pH 8) with 2 mM calcium chloride (as recommended by the supplier). A portion of the sample was mixed with equal parts of Matrix B (saturated α-cyano-4-hydroxy-cinnamic acid [CHCA; Sigma], in 50% aqueous acetonitrile, 0.1% trifluoro acetic acid) and analyzed by MALDI. The spectra were calibrated using protein standards that include insulin (5734.52 m/z), cytochrome c [M+H] (12360.97 m/z) and [M+2H] (6181.05 m/z), myoglobin [M+H] (16952.31 m/z) and [M+2H] (8476.66 m/z), and ubiquitin I (8565.76 m/z), and analyzed using MASCOT™ (Peptide Mass Fingerprint http://www.matrixscience.com/cgi/search_form.pl?FORMVER=2&SEARCH=PMF), to identify generated peptides. For the in-gel chymotrypsin digestion, treatment included reduction with 100 mM tris[2-carboxyethyl]phosphine (1 h, at room temperature) and alkylation with 100 mM iodoacetamide (1 h at room temperature in the dark).

For trypsin digestion, gel slices were washed in 100% acetonitrile for 10 min. Upon removal of the acetonitrile, slices were rehydrated and reduced in 10 mM DTT at room temperature for 30 min. The DTT solution was removed and proteins were alkylated with 50 mM iodoacetamide in 25 mM NH₄OAc at room temperature for 30 min. The alkylation solution was discarded and trypsin (20 ng/μl in 50 mM NH₄OAc) was added to the gel slice and the slice crushed using a pipet tip; the suspension was incubated for 30 min at 37°C. The solution containing the released peptides was removed to a clean tube and the gel fragments digested again with fresh protease at 37°C for 3 h. Solutions from the digests were combined, lyophilized to dryness and suspended in 12.5 μl of 20% aqueous acetonitrile. Peptides were prepared for MALDI using Zebra spin columns (Pierce). MS Digest (http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msdigest) and Peptide Cutter (http://web.expasy.org/peptide_cutter/) were used to prepare theoretical digests of TMEM184A for comparison with experimental masses.

Immunoprecipitation. Confluent 150 mm dishes of BAOECs, BAOSMCs, or A7r5s were harvested in radioimmunoprecipitation (RIPA) buffer (150 mM NaCl, 10μM Tris pH 7.2, 0.1% SDS, 0.1% Triton-X-100, and 0.5% deoxycholate) (Sigma), supplemented with two protease inhibitor cocktails (Sigma, P8340 and P2714) used at the manufacturer’s recommended concentrations. Briefly, 150 mm dishes were rinsed with cold PBS twice and incubated with 1 ml of RIPA buffer for 30 min at 4°C with rocking. Following this incubation, cells were scraped off the plates, placed in a microcentrifuge tube, and centrifuged for 10 min at 10,000 x g. The supernatant was mixed with 2 μg/ml of HRmAbs, or commercial TMEM184A antibodies, as noted in the text, and incubated overnight at 4°C on a rocker. After antibody incubation, 75 μl of equilibrated EZview red protein G affinity gel beads (Sigma) were added and incubated overnight at 4°C on a rocker. After incubation, the beads were rinsed with RIPA buffer three times and bound protein was released by boiling the beads in SDS sample buffer for 5 min. Western blots were performed as described below.

Western Blotting. Western Blotting for specific proteins was carried out after solubilizing cell samples into 2X sample buffer, boiling and separating by SDS-PAGE as above. Primary antibodies noted in the text, diluted by 1:1000.
TMEM184A is a vascular cell heparin receptor except for α-tubulin (1:8000). Blots in Figures 3A and 7A employed biotin-conjugated secondary antibodies (1:2000) and were developed using the ABC peroxidase staining kit and Pierce ECL Western Blotting substrate (Thermo Scientific, Waltham, MA) development system according to their recommended protocol. Blots in Figures 9A and D employed secondary antibodies conjugated to AlexaFluor 488®, AlexaFluor 594® or AlexaFluor 647® (diluted 1:5000) and visualization of bands was accomplished by fluorescence detection using the BioRad ChemiDoc MP system (#170-8280). Blots in Figure 7B and C employed biotin-conjugated secondary antibodies (1:2000) and were developed with an alkaline phosphatase, NBT/BCIP system as described previously (10, 14).

Indirect Immunofluorescence. For characterization of TMEM184A, cells were fixed with 4% paraformaldehyde (PFA) for 15 min, washed 3 times in PBS and permeabilized with 0.3% Triton-X-100 in PBS for 5 min. As noted, some experiments involved ice-cold methanol (MeOH) fixation instead of PFA. To stain for TMEM184A mostly on the cell surface, cells were fixed with methanol-free 4.0% PFA and were not permeabilized. The cover slips were incubated with primary antibodies against TMEM184A-NTD (dilution 1:200) specific for amino acid residues 11-63 near the N-terminus of human TMEM184A, TMEM184A-INT (dilution 1:100) specific for an internal region of TMEM184A developed for 20 amino acids between residues 250 and 300, or TMEM184A-CTD (dilution 1:200) specific for the C-terminal region developed for a 16 amino acid sequence near the C-terminus of TMEM184A overnight at 4 °C. Co-staining with TMEM184A-CTD or TMEM184A-NTD with TMEM184A-INT antibodies was done by incubating primary antibodies together or, in some cases, incubating with one of the primary antibodies for up to 12 h before adding the second primary antibody. Due to species identity, the TMEM184A-CTD and TMEM184A-NTD primary antibodies could not be used together. Cover slips were washed with PBS and incubated with minimal cross-reactivity secondary antibodies (1:200, except 1:100 for anti-goat antibodies) conjugated to AlexaFluor®488, tetramethylrhodamine isothiocyanate (TRITC), or AlexaFluor 647® (Jackson ImmunoResearch, West Grove, PA) for 2 h at room temperature or 45 min at 37 °C. Secondary antibody-only controls were performed and show virtually no non-specific interactions (data not shown). Cells were imaged using the Zeiss® LSM 510 Meta with a 63X oil-immersion lens at room temperature. Some A7r5 images were collected on a Nikon C2+ confocal microscope with a 60X oil-immersion lens at room temperature. All images in a set were taken at approximately the same Z-plane of the cell where intensity was the greatest. Gain intensity was set just below saturating levels for each protein of interest and those settings were used to image the remaining slides within a replicate.

**GFP-TMEM184A Expression.** A7r5s and BAOSMCs were transfected with 20 µg/ml of GFP-tagged TMEM184A plasmid (Origene, Rockville, MD) in the Bio-Rad Gene Pulser X-Cell System (Hercules, CA). Briefly, 100 mm confluent plates of cells were trypsinized, rinsed with PBS, suspended in HEPES-buffered saline, electroporated with a pre-set HeLa protocol (160 V modified to 170 V, 500μF capacitance, ∞Ω resistance), seeded onto glass cover slips in 6-well culture dishes, and fresh medium was added after approximately 24 h. BAOECs were transfected with GFP-TMEM184A using the same protocol with a pre-set CHO protocol (160V, 1 pulse of 15.0 ms pulse length). Exogenous GFP-TMEM184A expression was monitored by confocal microscopy after 24 h (BAOECs and BAOSMCs) and 48 h (A7r5s).

**Rhodamine-Heparin Binding and Uptake.** Incubation of GFP-TMEM184A transfected cells with 100 µg/ml rhodamine-conjugated heparin (Creative PEG Works, Winston-Salem, NC), for up to 10 min, was carried out in culture media followed by immediate fixation in 4% PFA without permeabilization, as above. Staining for TMEM184A, GFP-TMEM184A, and/or rhodamine-heparin was imaged by confocal microscopy as above. To quantify rhodamine-conjugated heparin uptake, cells were imaged as for functional studies below. Fluorescence in individual cells was determined using Image J, and the average uptake in A7r5 cells (more than 50) in
a given experiment was set as 1. Knockdown and transfected cell uptake was reported as compared to the A7r5 cells. For live imaging of heparin uptake, cells were grown in MatTek (Ashland, MA) 35 mm dishes as above for imaging after fixation. Individual dishes were moved to the confocal microscope after at least 24 h of culture, and heparin was added after cells were in focus. If uptake was not immediately visible, new regions were examined and the time post-heparin addition noted.

**TMEM184A Knockdown:** For siRNA-based confirmation of TMEM184A expression, A7r5 cells were transfected using 20 μg/ml rat TMEM184A siRNA or control siRNA (Santa Cruz) using the Bio-Rad Gene Pulser X-Cell System. Briefly, 100 mm confluent plates of cells were trypsinized, rinsed with PBS, suspended in HEPES-buffered saline, electroporated with the pre-set HeLa protocol (with preset voltage at 170), and seeded onto 100 mm dishes or glass cover slips in 6-well plates as described above.

For functional studies, A7r5 cells were transfected using 20 μg/ml of shRNA designed for rat TMEM184A in pGFP-V-RS plasmid or control nonsense shRNA in the same plasmid (Origene) using the Bio-Rad Gene Pulser X-Cell System as for the siRNA transfection. Four shRNA constructs were tested for knockdown ability. Constructs “B” and “C” were identified as the most effective in the A7r5 cells. Thereafter, all knockdown experiments employed one of these constructs. Fresh medium was added after approximately 24 h. Identification of TMEM184A knockdown involved staining for TMEM184A in cells that were fixed with 4% PFA, but without detergent or methanol, to observe surface protein specifically. For some experiments, knockdown was also analyzed with western blotting. After approximately 72 h post-electroporation, cells were treated with heparin at 200 μg/ml heparin for 20 min. Cells were then activated with PDGF with or without a 20 min heparin (200 µg/mL) pretreatment. Untreated cells served as controls. Each condition was tested with cells containing control shRNA and with cells containing the shRNA against TMEM184A. Cells treated with PFA and permeabilized with Triton-X-100 were stained for pERK or pElk as described previously (14) to determine heparin effects.

Stable transfection of A7r5 cells was accomplished by transfecting the TMEM184A shRNA construct (which contains a puromycin selection gene) as above, and plating cells onto 100 mm dishes for normal growth. 48 h post-electroporation, fresh MEM culture medium containing 3 μg/ml puromycin was added. Medium containing 3 μg/ml puromycin was changed every two days for a total of 8 days. Viability was low, but several small colonies remained and were transferred to a 35 mm dish. Cells were maintained in puromycin selection medium for 7 more days. Cells were then removed from puromycin and analyzed for GFP and TMEM184A expression. All cells expressed varying levels of GFP, and limited TMEM184A compared to control A7r5 cells. Stably transfected cells were employed in rhodamine-heparin uptake and DUSP1 induction as described.

DUSP1 induction was determined with cells stably transfected for TMEM184A knockdown. After seeding, stable knockdowns were transferred to FBS-free medium to facilitate optimal DUSP1 induction. Heparin was added to cells after 48 h in FBS-free medium at 200 μg/ml for 10, 20 or 30 min and nuclear DUSP1 levels were determined as described (14). TMEM184A levels were confirmed by immunofluorescence and western blotting.

**BrdU Incorporation Assay:** To evaluate cell proliferation in knockdown cells, A7r5s were electroporated with TMEM184A or control shRNA as above and seeded onto glass cover slips in 6-well plates. Fresh medium was not added for these experiments. 72 h post electroporation, 0.03 mg/ml BrdU was added to the medium for each well. 6 h after BrdU addition, cells were treated with PDGF with, or without, a 20 min heparin (200 μg/mL) pretreatment. Control cells were left untreated. After 24 h, cover slips were washed with cold 70% ethanol for 5 min at room temperature. Cover slips were washed with PBS (three times) and incubated with 1.5 M HCl for 30 min at room temperature. Cover slips were washed with PBS and incubated in a blocking buffer (1X PBS / 5% bovine serum albumin / 0.3% Triton-X-100) for at least 1 h at room temperature. Cover slips were incubated with anti-BrdU
primary antibody (1:50) overnight at 4˚C. Cover slips were washed with PBS and incubated with anti-mouse secondary antibody (1:200) for 45 min at 37˚C, washed again, mounted with Mowiol, and observed using a Nikon eclipse TE 2000-U fluorescence microscope.

**Quantitative RT-PCR (qRT-PCR).** A7r5s were transfected with TMEM184A or control siRNA as described and seeded onto 100 mm dishes. RNA was isolated using the Qiagen RNeasy total RNA isolation kit with optional on-column DNase digestion. Reverse transcription of 5 µg total RNA was performed with SuperScript III First-Strand Synthesis Super Mix reagents (Invitrogen). RT-PCR reactions were set up using the Qiagen QuantiTect SYBR® Green PCR kit. GAPDH was used as an internal control for normalization (GAPDH and TMEM184A primers were from Qiagen). RT-PCR cycling was performed with Qiagen RotorGene. RT-PCR data was analyzed using the 2^-ΔΔCt method to determine relative TMEM184A expression.

**Heparin Binding Assay.** BAOECs were electroporated with 20µg/mL GFP-TMEM184A vector and seeded into a 150 mm plate. 72 h post electroporation, cells were harvested in 0.2% CHAPS/PBS (as above) on ice with protease inhibitor cocktail P2714 (Sigma). To purify the GFP-TMEM184A, 2 µg/ml biotinylated anti-GFP antibody was added to the solution and incubated overnight at 4˚C with rocking. Streptavidin-agarose beads (Sigma, S1638) were washed three times with 10 column volumes of 0.2% CHAPS/PBS before being added to the solution and incubated overnight at 4˚C with rocking. Following this incubation, the solution was washed three times with 0.2% CHAPS/PBS before incubation with 0.2 M glycine/0.2% CHAPS/PBS on ice for 3 min with occasional gentle mixing. Beads were removed by centrifugation. The supernatant was neutralized with 1 M sodium bicarbonate. Sample was concentrated and exchanged into 0.2% CHAPS/PBS as above for large-scale preparations of wild-type TMEM184A. For comparison, GFP was purified from BAOECs identically to the GFP-TMEM184A. Preparations were made under bright light to bleach GFP fluorescence.

Black NeutrAvidin 96 well dishes (ThermoFisher Scientific) and black non-coated plates were washed with CHAPS/PBS. Biotinylated anti-GFP (60 pmol/well) was added to appropriate wells in the NeutrAvidin plate and incubated for 2 h at room temperature with shaking. Wells were washed three times for 5 min with 0.2% CHAPS/PBS with shaking. GFP-TMEM184A (approximately 5 nmol/well) was added to appropriate wells and incubated for 1 h at room temperature with shaking. Wells were washed three times, as above, with 0.2% CHAPS/PBS. Identical wells were prepared with GFP. Various concentrations of fluorescein-conjugated heparin (Creative PEG Works) were prepared in 0.2% CHAPS/PBS, added to appropriate wells, and incubated for 10 min at room temperature with shaking. All samples were prepared in triplicate. Fluorescein emission (λ_ex = 494 nm; λ_em = 519 nm) from the plate with bound GFP-TMEM184A was read initially after addition of heparin (complete wells) to obtain total fluorescence (TECAN Infinite® m200 Pro plate reader). The instrument gain was adjusted to ensure detection of heparin between 10 and 200 µg/ml heparin added. Unbound fluorescein-conjugated heparin was removed from wells coated with immobilized GFP-TMEM184A and was placed into wells in the non-coated black plates. 0.2% CHAPS/PBS was added back into wells from which heparin was removed. Fluorescein emission from the plate with bound GFP-TMEM184A was read, and then the 0.2% CHAPS/PBS containing residual unbound fluorescein-heparin was removed and fresh 0.2% CHAPS/PBS was added to the GFP-TMEM184A-bound wells. Unbound fluorescein-heparin was placed in empty wells and those wells were read to facilitate calculations of bound and unbound heparin. Wells without antibody and GFP-TMEM184A were prepared with the fluorescein-conjugated heparin dilutions to serve as standards. Fluorescein emission from the plate with bound GFP-TMEM184A was read after the final wash to obtain values for bound heparin. Emission values for triplicate samples were plotted after correction for protein without heparin background readings in control wells in each plate. Emission values from the complete wells were used to determine total
heparin added, and the bound value was determined from the emission value after the wash. Free heparin was calculated from the difference between the original and final fluorescence in the plate. These calculations were necessary because there was more quenching of fluorescence in the presence of antibody or antibody and antigen than in the wells of either dish without added proteins.

Statistical Analysis. Mean nuclear fluorescence intensities are shown as means +/- S.E. Comparisons between groups were analyzed using analysis of variance followed by a Tukey post hoc test. Comparisons between two groups were analyzed using a Student’s t test. Differences with p < 0.05 were considered significant. Refer to figure legends for statistical significance.

RESULTS

**TMEM184A is identified by HRmAb-based purification.** Heparin affinity chromatography and HRmAb-based affinity chromatography were employed to isolate heparin receptor from BAOECs, where the HRmAb ability to block heparin binding was first identified (5). Detailed procedures for isolation of the putative heparin receptor are described in the Methods. In brief, BAOECs were removed from culture dishes by scraping in ice-cold PBS supplemented with protease inhibitors. The cells were homogenized, debris cleared and membrane fractions were obtained after high-speed centrifugation. 0.2% CHAPS /PBS was then employed to solubilize membrane proteins, and a heparin binding fraction was obtained. The proteins that bound to a heparin column in 0.2% CHAPS/PBS buffer were then subjected to second affinity step involving HRmAbs which remained associated with streptavidin magnetic beads. Isolated putative receptor was analyzed by SDS-PAGE and stained for total protein (Figure 1A). Approximate molecular weights of various receptor preparations were determined by SDS-PAGE to be 52 to 58 kDa. Isolated protein was subjected to SDS-PAGE under reducing conditions and the band of interest excised from the gel after Coomassie staining of an equivalent separate lane or, in some instances, after staining with SYPRO Ruby. The MALDI spectrum of protein from a gel slice shows a molecular weight in the 47.4 kDa range (Figure 1B), while a solution sample of affinity-purified protein, not run on a gel, but extracted with cold acetone (to remove CHAPS and any tightly-bound lipid) shows a molecular weight of approximately 45.5 kDa. MALDI spectra of solution (detergent-solubilized) heparin receptor could not be obtained without solvent extraction; when extracted with acetone, the protein shown in 1C stayed soluble in the acetone. Additional experiments with ethyl acetate-extracted solution samples, gave masses of 45,877 and 48,149.3 (data not shown). Whereas the masses obtained by MALDI were much lower than the molecular weight of approximately 53 kDa determined by SDS-PAGE, the MALDI masses are closer to those obtained by SDS-PAGE of prior analytical preparations (5,10).

Intact receptor was separated by gel electrophoresis, stained with SYPRO Ruby, and stained receptor bands were cut out of the gel. These gel slices were crushed and digested with chymotrypsin as in Methods and analyzed by MALDI followed by MASCOT analysis for possible protein matches. Two separate analytical runs returned peptide matches for TMEM184A (Table I). Similar gel samples and soluble receptor samples were digested with trypsin. MS Digest and ExPASY’s Peptide Cutter (see Methods) were used to prepare theoretical digests of TMEM184A for comparison with experimental masses (Table II). Together, several different analyses resulted in peptides that covered 75 percent of the TMEM184A sequence. Figure 2 summarizes all of the chymotrypsin and trypsin digest data.

**Primary and cloned vascular cells express TMEM184A.** Protein analyses suggested TMEM184A as a heparin receptor candidate. Therefore, the expression of TMEM184A and its location(s) in cells were investigated in BAOECs and BAOSMCs. Whole cell western blots were carried out for BAOECs and BAOSMCs using the NTD commercial antibody. As shown in Figure 3A, distinct bands are present in the predicted molecular weight range of TMEM184A that are
absent from secondary antibody only controls. The doublet bands in BAOSMC samples could be due to post-translational modifications (e.g. glycosylation) which have been identified in mouse TMEM184A proteins (25). However, modifications in mouse samples resulted in high molecular weight protein. High molecular weight TMEM184A was not typically identified in our studies. NTD antibody staining of primary BAOECs and BAOSMCs showed cell surface staining with regions of varying intensity in cells fixed with PFA and not permeabilized (Figure 3B). In permeabilized cells, the antibody stained mostly a perinuclear region.

Two additional commercially available polyclonal antibodies raised to different regions of the human TMEM184A protein were employed to confirm TMEM184A presence and localization in vascular cells. As shown in Figure 3C, cells that were fixed with PFA (but not permeabilized) show specific staining patterns with the CTD antibody as well, consistent with presence at the plasma membrane. In permeabilized cells (Figure 3C) TMEM184A was detectable by confocal microscopy in the perinuclear region, consistent with reports of TMEM184A in Sertoli cells and exocrine cells (25,26). These studies also indicated colocalization with VAMP. Our vascular cells express a large amount of VAMP, which is diffuse in vesicles throughout the cytoplasm with intense clusters in defined perinuclear regions where it colocalized with TMEM184A (data not shown). The CTD staining was also localized to the membrane and to cytoplasmic vesicles, with broader distribution than the NTD staining. The INT antibody stained in a pattern similar to both NTD and CTD staining. This antibody stained membrane, the perinuclear region, and cytoplasmic vesicles (Figure 3C).

To further examine the differences in staining between the three commercial antibodies, cells were stained with pairs of these antibodies. One example of each antibody pair used to stain BAOECs is illustrated in Figure 3 (D, E). Obtaining clear images using co-staining with either NTD and INT antibodies or CTD and INT antibodies was difficult because the staining by each antibody appeared to be negatively impacted by the other antibody used. When added together, either the NTD or the CTD antibody resulted in limited staining by the INT antibody. When the INT antibody was added first, the staining of the CTD or NTD antibody declined somewhat. Because the NTD and CTD antibodies were both produced in rabbit, this pair was not tested. These results suggest that the antibody pairs evaluated interfere with each other, presumably by steric hindrance between the primary (and/or secondary) antibodies. Differences in staining could be due to differential antibody accessibility, localization of epitopes on different faces of the membrane, or some combination of these factors. Nevertheless, significant colocalization of antibody pairs is seen in dually-stained cells. The colocalization observed represents evidence for TMEM184A localization at the cell surface and in the perinuclear region along with some staining of other vesicles. Thus, we identified the candidate heparin receptor in bovine vascular cells.

To confirm the presence of TMEM184A in vascular cells of other species, primary and cloned rat VSMCs were examined. Similar staining occurred in both RAOSMCs and cloned A7r5 cells indicating that the staining was not specific to bovine cells or primary cells (Figure 4A). In addition, HBMECs express TMEM184A (Figure 4B). In all of these cells, localization appears similar to that observed in BAOECs and BAOSMCs. The presence of TMEM184A in vascular cells is consistent with its identification as a heparin receptor.

To confirm specificity for the antibody detection of TMEM184A, A7r5 cells were treated with either species-specific siRNA for TMEM184A or control siRNA, and stained for TMEM184A (Figure 5A). The TMEM184A staining in PFA fixed cells decreased in knockdown cells as compared to control siRNA treated cells. To ensure that TMEM184A mRNA was decreased by this technology, mRNA was prepared, and qRT-PCR was performed as described in Methods. As expected, Figure 5B illustrates that there was a significant decrease in the level of TMEM184A mRNA after knockdown indicating that mRNA for TMEM184A was also present. The knockdown of message as well as
TMEM184A is a vascular cell heparin receptor

The sub-cellular distribution of TMEM184A in vascular cells determined by antibody staining was confirmed by transfection of A7r5s, BAOECs, and BAOSMCs with GFP-TMEM184A. Significant expression of GFP-TMEM184A in the bovine cells occurred at about 24 h post transfection. The sub-cellular distribution of GFP-TMEM184A is similar to the membrane and perinuclear location seen with the antibody staining (Figure 5C), providing further evidence for the sub-cellular distribution of TMEM184A. Perinuclear staining in the bovine cells was more limited than in A7r5s where increased expression was observed at 48 h. Images of cells in Figure 5 indicate the range of GFP-TMEM184A localization observed in transfected cells. These results confirm that TMEM184A localizes to the plasma membrane and perinuclear regions in cultured vascular cells and indicate a range of intracellular distribution as seen with the TMEM184A antibodies (see Figure 3) rather than appearing identical to staining with any one of the antibodies. These data are consistent with TMEM184A identification as a heparin receptor.

**TMEM184A colocalizes with Caveolin in vascular cells.** The patchy surface staining suggested that plasma membrane TMEM184A might be clustered in membrane regions also containing caveolin, a protein with well-documented roles in membrane trafficking (reviewed in 27). We investigated the possibility that patches of TMEM184A were in regions containing caveolin by co-staining with commercial antibodies against both proteins. As predicted, we found co-localizing patches of both proteins in both ECs and VSMCs (Figure 6).

**HRmAbs immunoprecipitate TMEM184A.** TMEM184A is clearly expressed in cultured vascular cells and localized appropriately for a receptor that participates in endocytosis. To examine further whether the protein isolated with the HRmAbs was TMEM184A, vascular cell protein immunoprecipitated using the HRmAbs as described in Methods was analyzed by western blotting using commercial antibodies. HRmAb-precipitated samples from BAOECs (Figure 7A) were recognized using commercial TMEM184A antibody preparations. Affinity beads alone and beads with secondary antibody alone did not yield TMEM184A staining. Parallel immunoprecipitation from BAOECs (Figure 7B) and A7r5s (Figure 7C) with the HRmAbs and NTD antibodies resulted in identical western blot staining with INT antibodies. Therefore, the HRmAbs do bind to the TMEM184A protein, supporting its identification as the heparin receptor.

**Internalized heparin localizes with TMEM184A.** In order to support the hypothesis that TMEM184A is a receptor involved in heparin uptake, cells expressing GFP-TMEM184A were treated with rhodamine-heparin. Extensive colocalization was evident between GFP-TMEM184A and rhodamine-heparin at puncta throughout the cytoplasm (Figure 8). Cells that internalized rhodamine-heparin appeared to exhibit less characteristic surface GFP, suggesting that TMEM184A on the surface was internalized with the labeled heparin (Figure 8A). A7r5s expressing GFP-TMEM184A, but not treated with rhodamine-heparin, were used as control and showed insignificant levels of red auto-fluorescence (data not shown). To show that the rhodamine-heparin uptake depended on TMEM184A, A7r5s were stably transfected with the rat-specific TMEM184A shRNA construct as described in Methods. Rhodamine-heparin uptake was significantly decreased in A7r5 cells stably transfected as compared to normal A7r5 cells (Figure 8B). In addition, live imaging of A7r5s transfected with GFP-TMEM184A indicated that vesicles enclosed in GFP-TMEM184A stain contain rhodamine label, and these moved together (Figure 8C). Taken together, these results support the sub-cellular localization of TMEM184A in VSMCs and also provide evidence further supporting the identification of TMEM184A as a receptor for heparin. To evaluate the ability of TMEM184A to enhance heparin uptake, wild-type A7r5 cells, stable knockdown cells, and both of these cell types transfected with the GFP-TMEM184A construct were treated with rhodamine-heparin and analyzed for heparin uptake. Figure 8D illustrates average rhodamine label/cell from three separate experiments. As in
Figure 8B, stable knockdown cells took up significantly less labeled heparin. Transfection of the GFP-TMEM184A construct resulted in significant increases in rhodamine-heparin uptake for both the stable knockdown and A7r5 cells. Heparin uptake into the two transfected cell types was not significantly different.

**Knockdown of TMEM184A eliminates heparin effects in VSMCs.** To further examine the hypothesis that TMEM184A acts as a receptor for heparin, shRNA specific for rat TMEM184A was used to decrease TMEM184A expression in A7r5 cells. Transfection efficiencies of ~75% were consistently obtained in the A7r5 cell line (based on GFP expression also induced by the shRNA vectors). As shown in Figure 9A, TMEM184A levels are significantly reduced in 72 h TMEM184A shRNA-transfected cells relative to control shRNA-transfected cells.

Control shRNA-transfected cells exhibited a PDGF-induced increase in nuclear phosphorylated ERK (pERK) as we have seen previously in VSMC (14). Similarly, TMEM184A shRNA cells responded equally well to PDGF (Figure 9B). However, only control shRNA cells responded to heparin pretreatment with a significant decrease in nuclear pERK at both 10 and 20 min of PDGF (Figure 9B). Knockdown cells did not respond to heparin and had levels of nuclear pERK similar to those without heparin treatment (Figure 9B). PDGF treatment also induced a significant increase in phosphorylated Elk-1 (pElk) by 20 min, which was robustly attenuated by a 20 min heparin pretreatment prior to the PDGF treatment (Figure 9C). PDGF induced a smaller, but significant, increase in pElk-1 staining intensity in the TMEM184A shRNA-transfected cells. After knockdown of TMEM184A, the heparin-induced attenuation of PDGF-activated pElk-1 staining was lost (Figure 9C). Therefore, when TMEM184A levels were decreased, the cells no longer appeared sensitive to heparin. These results support the conclusion that TMEM184A is involved in mediating the heparin responses in VSMCs by serving as a receptor for heparin.

These data suggest that knockdown of TMEM184A would also decrease heparin induction of DUSP1 (24) which is required for heparin effects on ERK activity. Optimal heparin-induced expression of DUSP1 occurs in starved cells (24). However, no conditions to obtain significant knockdown of TMEM184A and the low levels of DUSP1 optimal for evaluating DUSP1 expression were found. Therefore, the cells stably transfected with the TMEM184A shRNA construct were evaluated. TMEM184A staining is shown in Figure 9D1. No evidence for heparin increases in DUSP1 was found in stable TMEM184A knockdown cells by evaluating nuclear DUSP1 levels (Figure 9D2). Western blots comparing the stable knockdown cells to A7r5 cells identically treated also identified no heparin induced increase in DUSP1 in cells lacking TMEM184A (Figure 9D3) while there was an increase in the A7r5 consistent with what we have observed previously in A7r5 cells (24). Again, these results indicate that TMEM184A functions as a receptor for heparin.

Because heparin decreases VSMC proliferation (e.g. 10), the effect of TMEM184A knockdown on heparin attenuation of PDGF-induced cell proliferation was examined using a BrdU incorporation assay. As shown in Figure 9E, a 20 min heparin treatment prior to PDGF stimulation greatly reduces BrdU incorporation in control cells. The anti-proliferative effect of heparin is eliminated in TMEM184A knockdown cells, where BrdU incorporation is actually increased above levels induced by PDGF alone. As with the previous results, these data indicate that the protein product of TMEM184A is needed for cells to respond typically to heparin. Taken together, the data indicate that decreasing TMEM184A expression results in decreased heparin sensitivity.

**Evidence that TMEM184A binds to heparin.** Together the preceding evidence indicates a role for TMEM184A in heparin uptake and heparin responses. Several pieces of evidence also suggest that TMEM184A binds to heparin. First, the purification of the putative receptor protein(s) for MALDI mass analyze utilized heparin affinity chromatography in PBS. Further, cellular protein isolated by HRmAb affinity procedures was examined for its ability to bind heparin: binding occurs in PBS and that binding decreases when
TMEM184A is a vascular cell heparin receptor

added sodium chloride reached approximately 0.5 M (5).

We examined the protein sequence of TMEM184A for sequences consistent with heparin binding. While there is no specific single heparin binding sequence, heparin and HS binding proteins typically have small clusters of basic amino acids, and often have additional basic amino acids further away in the linear sequence that are involved in heparin and/or HS binding (1). In fact, different sulfation patterns appear able to bind different sequences in HS binding proteins (e.g. 28). A portion of the bovine sequence for TMEM184A (amino acids 392 to the carboxyl terminus) is shown in Figure 10A; comparison to the human and rat sequences shows the presence of conserved basic amino acid clusters, that are conserved in many other species as well. There are additional basic amino acids between the last predicted transmembrane region and the C-terminal region shown, as well as in other regions of the protein that are not predicted to be membrane spanning. Thus, the sequence data are also consistent with identification of TMEM184A as a heparin/HS receptor.

Published evidence suggests some heparin effects in VSMC at 10 μg/ml, but most studies find that even 100 μg/ml does not completely saturate the heparin effects (9,29). We have previously reported significant heparin effects on VSMC DUSP1 synthesis as low as 50 μg/ml (24), but we have typically employed 200 μg/ml to match the responses to HRmAbs (10,24). To further examine the ability of TMEM184A to bind heparin, we used anti-GFP antibodies to pull down GFP-TMEM184A from transfected ECs. GFP for controls was obtained from transfected ECs using identical protocols. To perform a heparin binding assay, we treated the wells of NeutrAvidin-coated plates with biotin-tagged anti-GFP antibodies. Wells were incubated with GFP-TMEM184A or GFP control, and washed several times. Fluorescein-heparin was added to the wells and the total fluorescent signal was determined for each well. Figure 10B illustrates the signal over the heparin range from 10 μg/ml to 200 μg/ml heparin from the wells containing bound GFP-TMEM184A. After washing to remove unbound heparin, the fluorescence was again determined.

Figure 10C illustrates the heparin that bound to the immobilized GFP-TMEM184A or GFP control. In GFP-TMEM184A wells, the amount of bound heparin plateaued at approximately 100 pmol/well and between 25 and 50 μg/ml added heparin, but showed no binding to GFP only (control) wells (Figure 10C). Interestingly, above 50 μg/ml heparin, an increase in fluorescent heparin binding in GFP-TMEM184A-containing wells was detected. Heparin binding leveled off at approximately 100 μg/ml added heparin (Figure 10C). Heparin concentrations of approximately 70 μg/ml were required to achieve half-maximal binding.

An explanation for higher than expected heparin binding includes the possibility that GFP-TMEM184A associates into dimers or higher-order oligomers. Future studies aimed at determining the specific amino acid residues in TMEM184A required for heparin binding will be useful for a better understanding of heparin interactions with cells.

DISCUSSION

The very large number of proteins with which heparin interacts has made deciphering the specific protein(s) responsible for a given heparin response difficult. Our production of HRmAbs that were identified by their ability to block heparin binding to ECs facilitated studies characterizing cellular responses to heparin (5,10,14,24). The HRmAbs mimicked heparin-induced decreases in ERK activation and VSMC proliferation (10), as well as induction of DUSP1 and activation of PKG in the VSMC responses to heparin (14,24). Most recently, these antibodies have confirmed that at least some aspects of the anti-inflammatory effects of heparin on ECs are due to the same heparin binding site (8).

We report here the use of heparin-affinity chromatography followed by affinity purification of the HRmAb-interacting protein, our heparin receptor candidate. Mass spectral analysis of proteolytic peptides led us to identify the HRmAb-interacting protein as TMEM184A. Subsequently, we have shown that TMEM184A is present in both VSMCs and ECs, colocalizes with endocytosed heparin, binds heparin when isolated,
and is required for VSMC responses to heparin. Based on our previous signaling studies (10,14,24), and the heparin binding and knockdown data reported here, we propose a signaling pathway within VSMCs, beginning with TMEM184A heparin binding (Figure 11). Several steps, including whether the heparin receptor must be endocytosed for signaling, the protein(s) with which TMEM184A interacts, and the players involved in transmitting the information from activated PKG to the nucleus will require additional investigations. Several previous reports suggested that transactivation of the HB-EGFR and heparin blocking of that receptor function could account for heparin effects on VSMC (e.g. 21). However, some effects do not appear to occur through modification of growth factor signaling (15,24), and HRmAbs that mimic heparin effects also modulate intracellular signaling (e.g. 14). The data reported here support the identification of TMEM184A as the vascular cell receptor for heparin. To our knowledge this is the first identification of a receptor for heparin that is required for receptor-mediated heparin uptake and physiological effects in vascular cells.

There is very little published data on TMEM184A protein function. It has been identified in mice as a tissue specific, male germ-line cell membrane protein (26) that appears to be important in exocrine function (25). Its role in vesicle transport is consistent with the transport activities in ECs. Interestingly, the mouse protein is high molecular weight due to significant glycosylation (25,26). However, sequence data indicate an N-terminal extension in the mouse gene that may contain a glycosylation site that is not available or not used extensively in other species. Our data, with protein from several species, indicate molecular weights of affinity-purified heparin receptor are close to the predicted molecular weight of TMEM184A without glycosylation.

Heparin binding is critical to the isolation of the heparin receptor. An analysis of several predicted TMEM184A protein sequences (Figure 10) indicates that the C-terminal region is enriched in basic amino acids which could participate in heparin binding. There are other regions of the protein, which like the C-terminus are also not predicted to exist in transmembrane segments that contain multiple basic residues and may also participate in heparin binding. However, it will be necessary to determine binding of these regions to heparin before specific regions of the protein can be identified as critical for heparin interactions. In vivo it seems likely that the heparin receptor binds to HS chains, as it is true that heparin binding proteins often function in vivo by interacting with HS chains from HSPGs (1). Documentation of such interactions will also require additional investigations.

HSPGs in vascular cells have numerous functions that could involve the heparin receptor identified here. For example, abluminal HSPGs are critical for processing of lipoproteins by facilitating lipoprotein lipase transport (30), and HS is critical for clearance of triglyceride-rich lipoproteins in mice (31). HSPGs in ECs move in response to acute flow and accumulate near cell boundaries; in doing so they facilitate signal transduction. These changes are followed by longer term adjustment of other membrane molecules and cell alignment (32-34). Among the most studied are HS interactions with growth factors, cytokines, and their receptors (1), which are likely critical for the cell proliferation changes illustrated in Figure 9. In vivo, HSPGs might also normally interact with a heparin receptor resulting in modulation of growth factor responses in addition to functioning as a co-receptor for growth factors. Additional studies will be required to demonstrate that HS interactions with TMEM184A modulate vascular cell proliferation in vivo. However, decreased signaling through TMEM184A might well allow heparin to enhance cell proliferation through growth factor interactions as suggested by our results in the BrdU incorporation assay (Figure 9E).

Caveolae are non-clathrin-coated invaginations of the plasma membrane containing caveolin-1, are present in most mammalian cell types, and are particularly prominent in endothelial cells (35). Caveolins act as scaffolds in caveolae, which concentrate numerous receptors and signaling molecules involved in transport and signal transduction (27,35,36). The presence of TMEM184A in caveolae, as suggested by our data, would be consistent with our data indicating...
signaling from heparin in VSMCs (here and 14) and ECs (8). eNOS is also present in caveolae and plays a role in control of vascular reactivity and inflammation (36,37). Interestingly, cellular HSPGs are critical for eNOS activation in response to flow (34). It is also interesting that the HSPG, syndecan-1, requires lipid rafts (of which caveolae are a subset) for internalization (38). Involvement of the heparin receptor identified here, which results in PKG activation (14), could be part of the mechanism by which the system works.

Recently, an analysis of the heparin/HS glycomic interactome for angiogenesis has been published. This publication evaluates the large number of vascular proteins with roles in angiogenesis that can interact with heparin and HSPGs (20). The newly identified heparin receptor, TMEM184A, represents another relevant protein in this system. It will be important to determine whether HS chain association with the heparin receptor is required in any of these functions. The functions and dynamics of HSPGs are complicated. Their protein cores can be type I transmembrane proteins linked to the actin cytoskeleton with matrix metalloproteinase sensitive domains (which allow shedding of soluble ectodomains carrying HS chains), glycosylphosphatidylinositol-linked proteins requiring association with other membrane components to signal to the inside of the cell, or extracellular matrix proteins, which must link to the membrane through the HS chains and/or the protein core (reviewed in 39). The possibility that each of these HSPGs could also function through interactions between the HS chains and the heparin receptor, in cell types where it is expressed, significantly increases the possible mechanisms by which HSPGs can function. Ultimately, it will be important to determine which HSPG functions in vascular cells involve the heparin receptor identified here.

Studies of VSMC responses to heparin have long focused on effects of heparin and EC HS on VSMC proliferation and migration, key events during the development of atherosclerosis (40,41). HS chains are decreased by heparanase upregulation in atherosclerosis (reviewed in 42). In addition, glycocalyx HSPGs are expressed at higher levels in vascular areas subjected to laminar shear stress, which is known to impart atherosclerosis-resistance, than in regions of disturbed flow (43). Recent knockdown studies indicate that both syndecan-1 and -4 HSPGs are critical in the flow-induced protection of ECs (44,45). In this light, signaling through the TMEM184A heparin receptor provides one mechanism by which HS levels would elicit cellular change during the development of atherosclerosis. This first identification of a heparin receptor on VSMCs and its role in ECs (8) will now inform basic research to further understand the mechanisms by which TMEM184A contributes to vascular function, and, importantly, should facilitate a more directed approach to designing therapeutics that take advantage of vascular cell physiological changes in response to heparin.

ACKNOWLEDGEMENTS: *This work was supported by: Public Health Service; Contract grant number: HL54269 to LJLK. RJP’s Current address is Penn State University, 403 Wartik Laboratory, University Park, PA 16802. The authors recognize excellent technical help with MALDI-MS work contributed by Charles R. Schmidt and Haley Washburn at Lebanon Valley College and with initial TMEM184A immunoprecipitations by Michael Pavio from Lehigh University.

CONFLICT OF INTEREST: The authors declare that they have no conflicts of interest with the contents of this article.

AUTHOR CONTRIBUTIONS: LJL-K conceived and coordinated the study and led the paper writing. RJP and WAP conceived and carried out experiments in figures 1,2 and tables I, II. JBS conceived and carried out experiments in figures 3 through 8. SLNF conceived and carried out experiments in figures 3,4,5, 9, and 10 and helped to write the paper. YL carried out experiments in figures 7 and 8. TB carried out experiments in figure 9. All authors analyzed the results and approved the final version of the manuscript.
REFERENCES

1. Xu, D., and Esko, J. D. (2014) Demystifying heparan sulfate-protein interactions. Annu. Rev. Biochem. 83, 129-157

2. Ori, A., Wilkinson, M. C., and Fernig, D. G. (2011) A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J. Biol. Chem. 286, 19892-19904

3. Slee, J. B., Pugh, R., and Lowe-Krentz, L. (2012) Beyond anticoagulation: Roles for heparin in the vasculature. in Heparin: properties, uses and side effects (Liang, D. E. P. a. R. H. ed., Nova Sciences Publishers, Inc., New York

4. Bârzu, T., Molho, P., Tobelen, G., Petitou, M., and Caen, J. (1985) Binding and endocytosis of heparin by human endothelial cells in culture. Biochim. Biophys. Acta 845, 196-203

5. Patton, W. A. II, Granzow, C. A., Getts, L. A., Thomas, S. C., Zotter, L. M., Gunzel, K. A., and Lowe-Krentz, L. J. (1995) Identification of a heparin-binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells. Biochem. J. 311, 461-469

6. Thourani, V. H., Brar, S. S., Kennedy, T. P., Thronton, L. R., Watts, J. A., Ronson, Z. Q., Sturrock, A. L., Hoidal, J. R., and Vinten-Johansen, J. (2000) Nonanticoagulant heparin inhibits NF-kB activation and attenuates myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol 278, H2084-2093

7. Li, X., Zheng, Z., Mao, Y., and Ma, X. (2012) Unfractionated heparin promotes LPS-induced endothelial barrier dysfunction: a preliminary study on the roles of angiopoietin/Tie2 axis. Thromb. Res. 129, e223-228

8. Farwell, S., Kanyi, D., Hamel, M., Slee, J. B., Miller, E., Cipolle, M., and Lowe-Krentz, L. (2015) Heparin decreases in TNFα-induced endothelial stress responses require TMEM184A and induction of DUSP1

9. Castellot, J. J. J., Wong, K., Herman, B., Hoover, R. L., Albertini, D. F., Wright, T. C., Caleb, B. L., and Karnovsky, M. J. (1985) Binding and internalization of heparin by vascular smooth muscle cells. J. Cell. Physiol. 124, 13-20.

10. Savage, J. M., Gilotti, A. C., Granzow, C. A., Molina, F., and Lowe-Krentz, L. J. (2001) Antibodies against a heparin receptor slow cell proliferation and decrease MAPK activation in vascular smooth muscle cells. J. Cell. Physiol. 187, 283-293

11. Pukac, L. A., Carter, J. E., Ottlinger, M. E., and Karnovsky, M. J. (1997) Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells. J. Cell. Physiol. 172, 69-78

12. Ottlinger, M. E., Pukac, L. A., and Karnovsky, M. J. (1993) Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells. J. Biol. Chem. 268, 19173-19176
13. Pukac, L. A., Castellot, J. J. J., Wright, T. C., Caleb, B. L., and Karnovsky, M. J. (1990) Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. *Cell Regul.* **1**, 435-443.

14. Gilotti, A. C., Nimlamool, W., Pugh, R., Slee, J. B., Barthol, T., Miller, E., and Lowe-Krentz, L. (2014) Heparin responses in vascular smooth muscle cells involve cGMP dependent protein kinase. *J Cell Physiol* **229**, 2142-2152.

15. Fasciano, S., Patel, R., Handy, I., and Patel, C. (2005) Regulation of vascular smooth muscle proliferation by heparin. Inhibition of cyclin-dependent kinase 2 activity by p27kip1. *J. Biol. Chem.* **280**, 15682-15689.

16. Reilly, C., Kindy, M., Brown, K., Rosenberg, R., and Sonenshein, G. (1989) Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. *J. Biol. Chem.* **264**, 6990-6995.

17. Busch, S. J., Martin, G. A., Barnhart, R. L., Mano, M., Cardin, A. D., and Jackson, R. L. (1992) Trans-repressor activity of nuclear glycosaminoglycans on Fos and Jun/AP-1 oncoprotein-mediated transcription. *J. Cell Biol.* **116**, 31-42.

18. Hsia, E., Richardson, T. P., and Nugent, M. A. (2003) Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling. *J. Cell Biochem.* **88**, 1214-1225.

19. Stewart, M. D., Ramani, V. C., and Sanderson, R. D. (2015) Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk. *J. Biol. Chem.* **290**, 941-949.

20. Chiodelli, P., Bugatti, A., Urbinati, C., and Rusnati, M. (2015) Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use. *Molecules* **20**, 6342-6388.

21. Kalmes, A., Daum, G., and Clowes, A. W. (2001) EGFR transactivation in the regulation of SMC function. *Ann. N. Y. Acad. Sci.* **947**, 42-54; discussion 54-45.

22. Xie-Zukauskas, H., Das, J., Short, B. L., Gutkind, J. S., and Ray, P. E. (2013) Heparin inhibits angiotensin II-induced vasoconstriction on isolated mouse mesenteric resistance arteries through Rho-A- and PKA-dependent pathways. *Vascular pharmacology* **58**, 313-318.

23. Rauch, B., Millette, E., Kenagy, R., Daum, G., Fischer, J., and Clowes, A. W. (2005) Syndecan-4 is required for thrombin-induced migration and proliferation in human vascular smooth muscle cells. *J. Biol. Chem.* **280**, 17507-17511.

24. Blaukovitch, C. I., Pugh, R., Gilotti, A. C., Kanyi, D., and Lowe-Krentz, L. J. (2010) Heparin treatment of vascular smooth muscle cells results in the synthesis of the dual-specificity phosphatase MKP-1. *J. Cell. Biochem.* **110**, 382-391.

25. Best, D., and Adams, I. R. (2009) Sdmg1 is a component of secretory granules in mouse secretory exocrine tissues. *Dev. Dyn.* **238**, 223-231.
26. Best, D., Sahlender, D. A., Walther, N., Peden, A. A., and Adams, I. R. (2008) Sdmg1 is a conserved transmembrane protein associated with germ cell sex determination and germline-soma interactions in mice. Development 135, 1415-1425

27. Parton, R. G., and Simons, K. (2007) The multiple faces of caveolae. Nat Rev Mol Cell Biol 8, 185-194

28. Singh, A., Kett, W. C., Severin, I. C., Agyekum, I., Duan, J., Amster, I. J., Proudfoot, A. E., Coombe, D. R., and Woods, R. J. (2015) The Interaction of Heparin Tetrasaccharides with Chemokine CCL5 Is Modulated by Sulfation Pattern and pH. J. Biol. Chem. 290, 15421-15436

29. Castellot, J. J., Jr., Addonizio, M. L., Rosenberg, R., and Karnovsky, M. J. (1981) Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J. Cell Biol. 90, 372-379

30. Obunike, J. C., Lutz, E. P., Li, Z., Paka, L., Katopodis, T., Strickland, D. K., Kozarsky, K. F., Pillarissetti, S., and Goldberg, I. J. (2009) Transcytosis of lipoprotein lipase across cultured endothelial cells requires both heparan sulfate proteoglycans and the very low density lipoprotein receptor. J. Biol. Chem. 276, 8934-8941

31. Stanford, K. I., Bishop, J. R., Foley, E. M., Gonzales, J. C., Niesman, I. R., Witztum, J. L., and Esko, J. D. (2009) Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J. Clin. Invest. 119, 3236-3245

32. Zeng, Y., Waters, M., Andrews, A., Honarmandi, P., Ebong, E. E., Rizzo, V., and Tarbell, J. M. (2013) Fluid shear stress induces the clustering of heparan sulfate via mobility of glypican-1 in lipid rafts. Am J Physiol Heart Circ Physiol 305, H811-820

33. Zeng, Y., and Tarbell, J. M. (2014) The adaptive remodeling of endothelial glycocalyx in response to fluid shear stress. PLoS One 9, e86249

34. Ebong, E. E., Lopez-Quintero, S. V., Rizzo, V., Spray, D. C., and Tarbell, J. M. (2014) Shear-induced endothelial NOS activation and remodeling via heparan sulfate, glypican-1, and syndecan-1. Integr Biol (Camb) 6, 338-347

35. Sowa, G. (2012) Caveolae, caveolins, cavins, and endothelial cell function: new insights. Front Physiol 2, 120

36. Rath, G., Dessy, C., and Feron, O. (2009) Caveolae, caveolin and control of vascular tone: nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF) regulation. J. Physiol. Pharmacol. 60 Suppl 4, 105-109

37. Chidlow, J. H., Jr., and Sessa, W. C. (2010) Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation. Cardiovasc. Res. 86, 219-225

38. Chen, K., and Williams, K. J. (2013) Molecular mediators for raft-dependent endocytosis of syndecan-1, a highly conserved, multifunctional receptor. J. Biol. Chem. 288, 13988-13999

18
39. Couchman, J. R., Gopal, S., Lim, H. C., Norgaard, S., and Multthaupt, H. A. (2015) Syndecans: from peripheral coreceptors to mainstream regulators of cell behaviour. *Int. J. Exp. Pathol.* **96**, 1-10

40. Clowes, A. W., and Karnovsky, M. J. (1977) Suppression by heparin of smooth muscle cell proliferation in injured arteries. *Nature* **265**, 625-626.

41. Marcum, J., Atha, D., Fritz, L., Nawroth, P. P., Stern, D. M., and Rosenberg, R. (1986) Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycans. *J. Biol. Chem.* **261**, 7507-7517

42. Vlodavsky, I., Blich, M., Li, J.-P., Sanderson, R. D., and Ilan, N. (2013) Involvement of heparanase in atherosclerosis and other vessel wall pathologies. *Matrix Biol.* **32**, 241-251

43. Koo, A., Dewey, C. F., Jr., and Garcia-Cardena, G. (2013) Hemodynamic shear stress characteristic of atherosclerosis-resistant regions promotes glycocalyx formation in cultured endothelial cells. *Am J Physiol Cell Physiol* **304**, C137-146

44. Baeyens, N., Mulligan-Kehoe, M. J., Corti, F., Simon, D. D., Ross, T. D., Rhodes, J. M., Wang, T. Z., Mejean, C. O., Simons, M., Humphrey, J., and Schwartz, M. A. (2014) Syndecan 4 is required for endothelial alignment in flow and atheroprotective signaling. *Proc. Natl. Acad. Sci.* **111**, 17308-17313

45. Voyvodic, P. L., Min, D., Liu, R., Williams, E., Chitalia, V., Dunn, A. K., and Baker, A. B. (2014) Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow. *J. Biol. Chem.* **289**, 9547-9559

Footnotes:
†RJP and JBS contributed equally to this work
**To whom correspondence should be addressed. Phone: (610)758-5084; Fax: (610)758-4004; e-mail: ljl0@lehigh.edu

5Abbreviations: BAOECs-bovine aortic endothelial cells, BAOSMCs-bovine aortic smooth muscle cells, BCIP-5-Bromo-4-chloro-3-indolyl phosphate, CHCA-α-cyano hydroxy cinnamic acid, CTD- commercial antibody to a carboxy-terminal domain of TMEM184A, DUSP1-dual specificity phosphatase 1, EC-endothelial cell, HBMECs-human brain microvessel endothelial cells, HRmAbs-heparin-receptor monoclonal antibodies, HS-heparan sulfate, INT- commercial antibody to internal sequence of TMEM184A, MALDI-MS-matrix-assisted laser desorption/ionization mass spectrometry, MeOH-methanol, NBT-nitro blue tetrazolium, NTD-commercial antibody to the amino-terminal domain of TMEM184A, pElk-phosphorylated Elk-1, pERK-phosphorylated ERK, PFA-paraformaldehyde, PKG-cGMP-dependent protein kinase, qRT-PCR-quantitative RT-PCR, RAOSMCs-rat aortic smooth muscle cells, RIPA-radioimmunoprecipitation, TMEM184A-transmembrane protein 184A, TRITC-tetramethylrhodamine isothiocyanate, VSMC-vascular smooth muscle cell

FIGURE LEGENDS

**Figure 1. Analysis of protein isolated with HRmAbs.** Panel A. Analytical amounts of protein isolated as described in Methods were separated by SDS PAGE and stained with Coomassie blue (lane 1) or
TMEM184A is a vascular cell heparin receptor

transferred to nitrocellulose and stained for protein with colloidal gold (lane 2). A complete preparation was loaded onto a gel and stained with SYPRO Ruby (lane 3). Panel B. MALDI analysis of affinity-purified protein recovered from an acrylamide gel slice. Panel C. MALDI analysis of detergent-solubilized, affinity-purified protein prepared for analysis by acetone extraction (spectrum is of acetone soluble material).

**Figure 2. Receptor peptide analysis in TMEM184A gene sequence.** Chymotrypsin and trypsin generated peptides were mapped onto the bovine TMEM184A gene sequence to examine the extent of gene coverage. Red and green underlines indicate chymotrypsin generated peptides from Table I. Blue and purple underlines represent matches from trypsin digests described in Table II.

**Figure 3: TMEM184A is expressed in vascular cells.** Panel A. Whole cell lysates were immunoblotted for TMEM184A-NTD or compared to corresponding secondary antibody only controls. Panel B. Cells were fixed with ice-cold methanol or 4% PFA without permeabilization, as noted, and stained for TMEM184A-NTD. Panel C. Cells were stained with the TMEM184A-INT, and CTD antibodies. Panel D. BAOECs were fixed with 4% PFA without permeabilization and stained concurrently with TMEM184A-INT and TMEM184A-CTD primary antibodies. The contrast of the INT antibody image was increased in Fireworks™ and the brightness of the CTD image was decreased to better visualize the areas of colocalization. Panel E. BAOECs were fixed as in D and stained with TMEM184A-INT and TMEM184A-NTD. However, the NTD primary antibodies were added 8 h after INT antibodies. The INT image brightness was decreased and the NTD image contrast increased in Fireworks™ to visualize areas of colocalization. All images were obtained using confocal microscopy. Western Blots and images are all representative of at least three repeats. Scale bars = 10 µm.

**Figure 4: Rat and human vascular cells express TMEM184A.** Panel A. Primary RAOSMCs and cloned A7r5s were stained with the NTD and CTD antibodies after either methanol or PFA fixation as described in Figure 3. Panel B. HBMECs were stained with the NTD antibodies. Images are representative of at least three repeats. Scale bars = 10 µm.

**Figure 5. Validation of TMEM184A using TMEM184A siRNA and GFP-TMEM184A expression.** Panel A. A7r5s were electroporated with control siRNA or TMEM184A siRNA, and cells were fixed with 4% PFA, stained for TMEM184A-INT on the surface of cells, and imaged with confocal microscopy. Panel B. A7r5 cells were treated with scrambled or siRNA for TMEM184A. After 24 h, RNA was prepared and RT PCR carried out as described. The graph indicates differences in RNA. Panel C. A7r5s, BAOECs, and BAOSMCs were electroporated with 20 µg/ml of GFP-TMEM184A and allowed to proliferate for 24 hr (BAOECs and BAOSMCs) or 48 h (A7r5s), following which they were fixed with 4% PFA. Images on the right column were magnified 2X the boxed area on the left. All images are representative of at least three repeats. Scale bars = 10 µm.

**Figure 6: TMEM184A colocalizes with caveolin-1.** RAOSMCs and BAOECs were fixed and permeabilized with 4% PFA and 0.3% Triton. Cells were treated with antibodies specific for TMEM184A-NTD (Red) and cav-1 (Green). Far right column is magnified 4X the original boxed area in the panel immediately to the left. Images are representative of at least three repeats. Scale bars = 10 µm.

**Figure 7. Immunoprecipitation of the heparin receptor detects TMEM184A.** Panel A. BAOECs were harvested for immunoprecipitation as described in methods section. Cell lysates were incubated with HRmAbs 12B1 or 18E9 and precipitated using EZview affinity beads. One-fourth of the final sample was developed with NTD, CTD, or secondary only antibodies. Similar BAOEC lysates in Panel B and A7r5 lysates in panel C were divided into identical fractions and incubated with 12B1, commercial NTD TMEM antibody, or beads alone. A whole cell sample was also used in B. Blots were developed using
INT TMEM184A antibody and are representative of three repeats. Bands near the bottom of the blots are also seen with secondary antibodies only. All blots were developed and converted to grayscale for post-hoc analysis as described in methods.

**Figure 8. GFP-Tagged TMEM184A colocalizes with Rhodamine-Heparin.** Panel A. A7r5s electroporated with GFP-TMEM184A as in Figure 5 were treated with 100 μg/ml rhodamine-heparin for the times indicated, following which they were fixed with 4% PFA. Images are representative of two separate experiments. Panel B. A7r5 and stable knockdowns for TMEM184A were treated with 100 μg/ml rhodamine-heparin for 10 min and fixed with 4% PFA. Images are representative of duplicates from two separate experiments. Scale bars for A, B = 10 μm. Panel C. GFP-TMEM184A transfected A7r5s were incubated with 200 μg/ml rhodamine-heparin, and cells were immediately imaged without fixing. Time lapse confocal microscopy initiated at about 4 min after heparin addition identified colocalization of rhodamine-heparin (white vertical line) with a cluster of the GFP-TMEM 184A construct. (Scan Zoom: 6.9, Objective: 63×/1.4 Oil DIC) Reference white bar points to the initial location and is a reference for concurrent movement of both labels. Scale bar for C = 2 μm. Panel D. A7r5 and stable knockdowns for TMEM184A (KD) were either transfected with GFP-TMEM184A construct or not and treated as in Panel B. At least 50 cells per condition (in each of three experiments) were analyzed for heparin uptake. **; p<0.0001.

**Figure 9. TMEM184A knockdown A7r5s do not respond to heparin.** A7r5s were electroporated with control shRNA or TMEM184A shRNA as in the Methods. Western blots indicating TMEM184A levels are shown in A (NT – untreated cells). Cells were treated with PDGF with or without heparin pretreatment and were fixed with 4% PFA, permeabilized with 0.3% Triton and stained for pERK (panel B) or pElk-1 (panel C). Panel D. Stable knockdown A7r5s were starved for 48 h, treated with heparin, fixed with 4% PFA, permeabilized with 0.3% Triton, and stained for DUSP1 (D1). Some cells were also stained for TMEM184A and compared to A7r5 parent cells (D1). Heparin treatments were run in duplicate and at least 500 cells were examined at each point (D2). Western blots below indicate DUSP1 levels for stable knockdown cells and parent A7r5 cells after 20 min heparin treatment (D3). Panel E. TMEM184A shRNA was used to knock down TMEM184A before addition of BrdU. Treatment with PDGF with or without heparin pretreatment was for 24 h and BrdU incorporation was measured. All graphs represent at least 200 cells from at least 3 separate experiments with SEM. *; p<0.05.

**Figure 10. Heparin binds to TMEM184A.** Panel A. The sequence of bovine TMEM184A was investigated for basic amino acid clusters. The most extensive cluster was found near the C-terminus (aa 392-414). Human and rat corresponding sequences are shown below. GFP-TMEM184A was isolated from transfected BAOECs in CHAPS/PBS and bound to NeutrAvidin-coated wells using biotinylated anti-GFP as described in Methods. GFP was prepared identically and used as a control. Various concentrations of fluorescein-conjugated heparin, from 10 to 200 μg/ml (10 μg/ml= 0.056 nmol, 25 μg/ml= 0.1389 nmol, 50 μg/ml= 0.2778 nmol, 75 μg/ml= 0.4167 nmol, 100 μg/ml= 0.5556 nmol, 200 μg/ml= 1.1111 nmol), were added (100 μl total volume), unbound heparin removed, and wells washed as described. Total heparin, bound heparin, and unbound heparin were determined by measuring emission at 519 nm. Triplicate samples are shown in Panel B for total heparin fluorescence readings and in Panel C for heparin binding to GFP-TMEM184A (squares) and to GFP control (circles).

**Figure 11. Predicted signal pathway from the heparin receptor.** Signaling from heparin through TMEM184A to the induction of DUSP1 and decrease in ERK activation.
Table I

Comparison of Theoretical Peptides from TMEM184A to Chymotryptic Peptides from Isolated Receptor

| Chymotrypsin generated peptides | Location* | Observed m/z | Theoretical m/z |
|---------------------------------|-----------|--------------|-----------------|
| TVPHEQRYIIRL                    | 72-83     | 1523.84      | 1522.8327       |
| QFCIVKPIMALVTIVL                | 178-193   | 1847.10      | 1846.0927       |
| CIVKPIMAL                      | 180-188   | 1046.70      | 1045.6927       |
| VYNASVSLALYALFLF                | 216-231   | 1790.10      | 1789.0927       |
| FLFYSATRELLQPF                 | 229-242   | 1733.10      | 1632.0927       |
| SEKTESSPAPSMQSISSGL             | 320-340   | 2091.39      | 2090.3827       |

Peptides were generated from bovine endothelial protein isolated using monoclonal antibodies against the heparin receptor. These peptides were identified by MASCOT as matching in TMEM184A (bovine) that had been alkylated prior to digestion.

*Refers to location in TMEM184A.
Peptides were generated from bovine endothelial protein isolated using monoclonal antibodies against the heparin receptor. This table shows only those peptides with 0 or 1 missed cleavage. Samples were carboxymethylated and analysis includes the possibility of modification.

* Location refers to their location in TMEM184A.

** Identified by Protein Prospector as high-confidence matches in one or more samples; many of these peptides were also seen in additional samples, but with lower confidence.

† Identified by Protein Prospector as lower-confidence matches in one or more samples.

a Peptides from in-gel digest; masses identified by PeptideCutter

b Peptides from in-gel digest; masses identified by MS Digest

c Peptides from expressed solution digest; masses identified by PeptideCutter

d Peptides from expressed solution digest; masses identified by MS Digest

Table II

Comparison of Theoretical Peptides from TMEM184A to Tryptic Peptides from Isolated Receptor Protein

| Trypsin -generated peptides | Location* | Observed m/z | Theoretical m/z ** | Notes |
|-----------------------------|-----------|--------------|-------------------|-------|
| TSCFHGTCCCLR                | 150-160   | 1285.35**    | 1285.5021         | b     |
| GMTYSIGFLR                  | 161-170   | 1144.11**    | 1145.3791         | a,b   |
| TSCFHGTCCLRGMYSIGFLR        | 150-170   | 2469.72**    | 2470.8903         | d     |
| QATLQFCIVKPIALVTIVLQAFGK    | 174-198   | 2733.10**    | 2734.4491         | c,d   |
| ETMSPDQDIVQDAIHNFSPAYQK     | 342-363   | 2518.66**    | 2520.7974         | c,d   |
| NVEKRMILPAEL                | 402-414   | 1542.01**    | 1542.8335         | a     |
| AGNGSQGPGLFLTSPLARGVSGVFWAALVLTGHQIYLHRL | 28-69 | 4356.05† | 4360.0665 | a,c |
| SYTVPHQR                    | 70-78     | 1114.84†     | 1117.2091         | a     |
| DCYEAFVIYSFLSCFQYLGESAIMAEIRGKPVR | 115-149 | 4093.54† | 4094.7040 | c,d |
| IHDGDFNVR                   | 199-207   | 1121.73†     | 1123.1694         | a,b,c,d |
| SGYLYITLVNASVSLALYALFLFYSATR | 208-236 | 3277.81     | 3281.8183         | c,d   |
| ELLOPFPVLK                  | 237-247   | 1310.42†     | 1313.5793         | a     |
| FLTIKAVIFLSFWQQLLAILER      | 248-270   | 2690†        | 2693.3385         | a,c,d |
| YAFTCQVYSEKTESSPAPSAPMQISSGLK | 312-341 | 3196.94† | 3196.5707 | a     |
| TESSPAPSAPMQISSGLKETMSPDIVQDAIHNFSPAYQK | 323-363 | 4373.82† | 4377.8412 | a,c,d |
| YTQQATQEPAPQGQVPSPR         | 364-384   | 2256.63†     | 2256.4394         | c,d   |
| TPTHSPDGPGGGR               | 385-398   | 1291.26†     | 1293.1769         | a,b,d |
| RMLIPAEEL                   | 406-414†  | 1069.28†     | 1072.3075         | c,d   |
Figure 1

A

B

C

Abundance

m/z

47,357

45,344
**Figure 2**

| 10  | 20  | 30  | 40  | 50  | 60  |
|-----|-----|-----|-----|-----|-----|
| MDTPGIICT | PLAWTPARP | AGQMEMRAON | CSQGPGPLF | TSPLARQVSG | VFWAALYLT |
| 70  | 80  | 90  | 100 | 110 | 120 |
| GHQYLLHRS | YTVPHQRYI | IRLFLIVVY | AFDSWLSLL | LGHQQHNYVF | DSVRDCYEAF |
| 130 | 140 | 150 | 160 | 170 | 180 |
| VYSSFLSICF | QLYGESAIM | AEIRGPKVRT | SRFQMTCCLR | QMTYSIGFLR | FCQATLQFC |
| 190 | 200 | 210 | 220 | 230 | 240 |
| IVKPMALYT | YLDGAFGKYH | DQGDNRSGY | LYITLVMAS | VSLAYALFL | FYSATFRILQ |
| 250 | 260 | 270 | 280 | 290 | 300 |
| PEEPVFLFLT | IKAVIFLSFW | QGLLAILIER | CVQPEQTVI | DGSTVAGFTV | AAYQYNTIC |
| 310 | 320 | 330 | 340 | 350 | 360 |
| IEMLFASIAL | RYAFTPQYV5 | EKETSSPAPS | APMQSTSSGL | KETMSPOQIV | QBASHNFSPA |
| 370 | 380 | 390 | 400 | 410 | 420 |
| YKQTQATQ | EAPPRPGQSGV | PSPRTYTHSP | DGGPQGRXG | RNVEKREMLIP | AEEL |
Figure 3

A

B

C

D

E

TMEM184A is a vascular cell heparin receptor
Figure 4

A

RAOSMCs

A7r5

B

HBMVECs

MeOH-NTD  4% PFA - NTD  MeOH-CTD  4% PFA - CTD
Figure 5

A

Control siRNA  TMEM184A siRNA

4% PFA only

B

Relative TMEM mRNA

0 0.5 1.0 1.5
Control siRNA TMEM siRNA

C

GFP-TMEM184A

Zoom 2X

A7r5s

BAOSMCs

BAOECs

TMEM184A is a vascular cell heparin receptor
Figure 6

TMEM184A is a vascular cell heparin receptor
Figure 7

A

52 IB NTD
52 IB CTD
52 IB - control
IP B1 E9

B

IB INT

WC B 12B1 NTD

C

IB INT

B 12B1 NTD

TMEM184A is a vascular cell heparin receptor
Figure 8

A: GFP-TMEM184A, Rhodamine, Heparin, Merge.

1 min, 3 min, 5 min.

B: A7r5, Stable knockdown, No Heparin.

C: Image with time points 0.000s, 17.379s, 34.769s, 52.139s, 69.519s, 88.899s, 104.279s.

D: Relative Fluorescence per Cell.

|            | A7r5 | A7r5 | KD  | KD  |
|------------|------|------|-----|-----|
| Transfected|      |      |     |     |
| TMEM184A   |      |      |     |     |

** *
TMEM184A is a vascular cell heparin receptor

Figure 9

A

B

C

D1

D2

D3

E

NTM184A
shRNA

Control shRNA

TMEM184A shRNA

NTD

Tubulin

Relative NEM184A

Control shRNA

TMEM184A shRNA

Heparin

PDGF

- - 10 min 10 min 20 min 20 min

Relative NEM184A

Relative NEM184A

Relative ERK

Relative ERK

Relative ERK

TMEM184A NTD

A7r5
Knockdown

Relative DUSP1

Minutes Heparin

Relative DUSP1

Relative DUSP1

Relative DUSP1

Relative DUSP1

Relative RadU Incorporation

Untreated

PDGF

Hep/PDGF

Untreated

PDGF

Hep/PDGF

Untreated

PDGF

Hep/PDGF

Untreated

PDGF

Hep/PDGF
Figure 10

A

GGPGGGGRKGRNVEKRMLIPAEEL  Bovine
GGSGGSRKRSLEKRMLIPSEDL  Human
SGSGGGKKSREIEKRMLIPDRFL  Rat

B

Relative Fluorescence

0.2 0.4 0.6 0.8 1.0
nmoles Heparin added

C

nmoles Heparin bound

50 100 150 200
μg/ml Heparin added
Figure 11
Transmembrane protein 184A is a receptor required for vascular smooth muscle cell responses to heparin
Raymond J. Pugh, Joshua B. Slee, Sara Lynn N. Farwell, Yaqiu Li, Trista Barthol, Walter A. Patton and Linda J. Lowe-Krentz

J. Biol. Chem. published online January 14, 2016

Access the most updated version of this article at doi: 10.1074/jbc.M115.681122

Alerts:
  • When this article is cited
  • When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts